Evidence for a new mechanism of ICT resistance is provided by differential expression of β2M/CD1d axis dependent on epigenetic alterations in the TME of metastatic melanoma, which is significantly associated with poor outcomes of metastatic melanoma patients receiving anti-PD1 immunotherapies (Figure 4). The gene discussed is CD1D; the disease is metastatic melanoma.